NeuroBo Pharmaceuticals ( (NRBO) ) has issued an announcement.
NeuroBo Pharmaceuticals has announced the completion of its Phase 2a clinical trial for DA-1241, an innovative treatment targeting metabolic dysfunction-associated steatohepatitis (MASH). The trial, which involved 109 patients, aims to assess the efficacy and safety of DA-1241 alone and in combination with sitagliptin. The company anticipates releasing topline data in December 2024, offering potential insights into DA-1241’s ability to improve liver inflammation and lipid metabolism, marking a significant step in combating MASH.
For detailed information about NRBO stock, go to TipRanks’ Stock Analysis page.
